Recursion Pharmaceuticals (NASDAQ:RXRX) Posts Earnings Results, Meets Expectations

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its earnings results on Monday. The company reported ($0.22) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.22), FiscalAI reports. The firm had revenue of $18.55 million during the quarter, compared to analyst estimates of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%.

Recursion Pharmaceuticals Stock Down 5.0%

NASDAQ RXRX traded down $0.20 during trading on Monday, reaching $3.83. 22,499,747 shares of the company’s stock traded hands, compared to its average volume of 19,653,320. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of -3.68 and a beta of 1.15. The company’s 50 day simple moving average is $3.74 and its two-hundred day simple moving average is $3.54. Recursion Pharmaceuticals has a 12-month low of $2.77 and a 12-month high of $5.76.

Analyst Ratings Changes

A number of brokerages recently weighed in on RXRX. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a report on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Monday, October 19th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.18.

Insider Activity

In related news, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total transaction of $125,000.00. Following the transaction, the director directly owned 162,156 shares of the company’s stock, valued at $810,780. This trade represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the transaction, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This trade represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 157,408 shares of company stock worth $643,576. Corporate insiders own 6.65% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.